Table 2.
Survivin immunoreactivity in pancreatic endocrine tumors (n = 111)
| Immunoreactivity | No. of patients | |||
|---|---|---|---|---|
| Total | Well-differentiated tumors | Well-differentiated carcinomas | Poorly differentiated carcinomas | |
| Nuclear survivin | ||||
| <5% | 80 (72%) | 23 (92%) | 44 (70%) | 2 (29%) |
| 5–50% | 21 (19%) | 2 (8%) | 12 (19%) | 3 (43%) |
| >50% | 10 (9%) | – | 7 (11%) | 2 (29%) |
| Cytoplasmic survivin | ||||
| <5% | 39 (35%) | 4 (16%) | 28 (44%) | 3 (43%) |
| 5–50% | 10 (9%) | — | 6 (10%) | 1 (14%) |
| >50% | 62 (56%) | 21 (84%) | 29 (46%) | 3 (33%) |
Total all specimens immunostained for survivin (n = 111). Well-differentiated tumors, Well-differentiated carcinomas, Poorly differentiated carcinomas: number of specimens immunostained for survivin when the WHO classification was available (n = 95)